$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 9 10 11 12 13
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Grant | A | 0.00 | 1,330 | 0 | 2,433 | 1.1 K to 2.4 K (+120.58 %) |
| May 09 2013 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 0.00 | 368 | 0 | 1,103 | 735 to 1.1 K (+50.07 %) |
| Apr 26 2013 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Sell | J | 0.00 | 700,000 | 0 | 0 | 700 K to 0 (-100.00 %) |
| Apr 17 2013 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 0.00 | 324 | 0 | 1,947 | |
| Apr 17 2013 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 0.00 | 324 | 0 | 649 | 325 to 649 (+99.69 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | M | 0.00 | 649 | 0 | 1,947 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Buy | M | 0.00 | 649 | 0 | 649 | 0 to 649 |
| Apr 15 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 649 | 0 | 1,947 | |
| Apr 15 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 649 | 0 | 2,151,283 | 2.2 M to 2.2 M (+0.03 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 6,490 | 0 | 14,279 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Payment of Exercise | F | 34.57 | 2,676 | 92,509 | 3,814 | 6.5 K to 3.8 K (-41.23 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 6,490 | 0 | 6,490 | 0 to 6.5 K |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 3,750 | 39,000 | 82,788 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 8,113 | 0 | 17,848 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Payment of Exercise | F | 34.57 | 3,049 | 105,404 | 5,064 | 8.1 K to 5.1 K (-37.58 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 8,113 | 0 | 8,113 | 0 to 8.1 K |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.50 | 2,100 | 72,450 | 0 | 2.1 K to 0 (-100.00 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.38 | 100 | 3,438 | 2,100 | 2.2 K to 2.1 K (-4.55 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.38 | 200 | 6,875 | 2,200 | 2.4 K to 2.2 K (-8.33 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.35 | 200 | 6,870 | 2,400 | 2.6 K to 2.4 K (-7.69 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.33 | 100 | 3,433 | 2,600 | 2.7 K to 2.6 K (-3.70 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.32 | 100 | 3,432 | 2,700 | 2.8 K to 2.7 K (-3.57 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.31 | 300 | 10,293 | 2,800 | 3.1 K to 2.8 K (-9.68 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.30 | 300 | 10,290 | 3,100 | 3.4 K to 3.1 K (-8.82 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.29 | 100 | 3,429 | 3,400 | 3.5 K to 3.4 K (-2.86 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 34.25 | 200 | 6,850 | 3,500 | 3.7 K to 3.5 K (-5.41 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 33.86 | 50 | 1,693 | 3,700 | 3.8 K to 3.7 K (-1.33 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 3,750 | 39,000 | 3,750 | 0 to 3.8 K |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 0.00 | 325 | 0 | 2,271 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 0.00 | 325 | 0 | 325 | 0 to 325 |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 0.00 | 24,339 | 0 | 53,545 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Payment of Exercise | F | 34.57 | 10,774 | 372,457 | 394,332 | 405.1 K to 394.3 K (-2.66 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 0.00 | 24,339 | 0 | 405,106 | 380.8 K to 405.1 K (+6.39 %) |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 3,245 | 0 | 7,139 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 3,245 | 0 | 3,245 | 0 to 3.2 K |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 0.00 | 649 | 0 | 1,947 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 0.00 | 649 | 0 | 649 | 0 to 649 |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 0.00 | 649 | 0 | 1,947 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 0.00 | 649 | 0 | 649 | 0 to 649 |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 0.00 | 735 | 0 | 2,207 | |
| Apr 11 2013 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 0.00 | 735 | 0 | 735 | 0 to 735 |
| Mar 06 2013 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commerical Of ... | Option Exercise | A | 37.69 | 130,000 | 4,899,700 | 130,000 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 21.50 | 11,249 | 241,854 | 11,249 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 0.00 | 2,596 | 0 | 2,596 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | A | 21.50 | 4,673 | 100,470 | 4,673 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | A | 0.00 | 2,942 | 0 | 2,942 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | A | 21.50 | 12,980 | 279,070 | 12,980 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | A | 0.00 | 2,596 | 0 | 2,596 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 9.31 | 4,759 | 44,306 | 4,759 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 21.50 | 5,538 | 119,067 | 5,538 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 0.00 | 2,942 | 0 | 2,942 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | A | 9.31 | 3,461 | 32,222 | 3,461 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | A | 21.50 | 3,288 | 70,692 | 3,288 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | A | 0.00 | 2,596 | 0 | 2,596 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | A | 21.50 | 11,249 | 241,854 | 11,249 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | A | 0.00 | 2,596 | 0 | 2,596 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | A | 21.50 | 51,922 | 1,116,323 | 51,922 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | A | 0.00 | 77,884 | 0 | 77,884 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Option Exercise | A | 21.50 | 17,307 | 372,101 | 17,307 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Option Exercise | A | 0.00 | 25,961 | 0 | 25,961 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 21.50 | 6,923 | 148,845 | 6,923 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 0.00 | 10,384 | 0 | 10,384 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 21.50 | 13,846 | 297,689 | 13,846 | |
| Nov 20 2012 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 0.00 | 20,769 | 0 | 20,769 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | A | 9.31 | 4,326 | 40,275 | 4,326 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | C | 0.00 | 4,500,000 | 0 | 0 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | C | 0.00 | 13,888,889 | 0 | 0 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | C | 0.00 | 13,888,889 | 0 | 0 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | P | 0.00 | 4,500,000 | 0 | 4,500,000 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Buy | C | 0.00 | 778,843 | 0 | 7,187,217 | 6.4 M to 7.2 M (+12.15 %) |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Buy | C | 0.00 | 2,403,837 | 0 | 6,408,374 | 4 M to 6.4 M (+60.03 %) |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Buy | C | 0.00 | 2,403,837 | 0 | 4,004,537 | 1.6 M to 4 M (+150.17 %) |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | P | 15.00 | 700,000 | 10,500,000 | 700,000 | 0 to 700 K |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | C | 0.00 | 10,500,000 | 0 | 0 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | P | 0.00 | 10,500,000 | 0 | 10,500,000 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Buy | P | 15.00 | 333,334 | 5,000,010 | 2,150,634 | 1.8 M to 2.2 M (+18.34 %) |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Buy | C | 0.00 | 1,817,300 | 0 | 1,817,300 | 0 to 1.8 M |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Option Exercise | C | 0.00 | 4,500,000 | 0 | 0 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Option Exercise | C | 0.00 | 13,888,889 | 0 | 0 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Option Exercise | C | 0.00 | 13,888,889 | 0 | 0 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Buy | C | 0.00 | 778,843 | 0 | 7,187,217 | 6.4 M to 7.2 M (+12.15 %) |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Buy | C | 0.00 | 2,403,837 | 0 | 6,408,374 | 4 M to 6.4 M (+60.03 %) |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Buy | C | 0.00 | 2,403,837 | 0 | 4,004,537 | 1.6 M to 4 M (+150.17 %) |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 10,500,000 | 0 | 0 | |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 15.00 | 333,334 | 5,000,010 | 2,150,634 | 1.8 M to 2.2 M (+18.34 %) |
| Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 1,817,300 | 0 | 1,817,300 | 0 to 1.8 M |